Vasogen Appoints Terry H. Gregg President & CEO



    MISSISSAUGA, ON, March 7 /CNW/ - Vasogen Inc. (NASDAQ:  VSGN; TSX:VAS), a
biotechnology Company focused on the research and commercial development of
technologies targeting the chronic inflammation underlying cardiovascular and
neurological disease, is pleased to announce that Terrance H. Gregg has
succeeded David G. Elsley as President and Chief Executive Officer of Vasogen.
Mr. Gregg joined Vasogen's Board of Directors in 1999, was appointed Vice
Chairman in November 2005, and became Chairman of the Board in March 2006.
David Elsley, who founded Vasogen, will remain a member of Vasogen's Board of
Directors and Mr. Gregg will retain his position as Chairman.
    In 1996, Mr. Gregg became President and Chief Operating Officer of
MiniMed Inc., now a world leader in insulin pump therapy and continuous
glucose monitoring, and was instrumental in Medtronic's US$3.4 billion
acquisition of the company in 2001. Mr. Gregg retired as President of
Medtronic MiniMed in 2002. He also served in executive positions with Smith &
Nephew plc, a diversified healthcare product company, and Allergan, Inc., a
leading ophthalmic device and pharmaceutical company. He is currently a
Special Venture Partner with Galen Associates, a private equity firm
specializing in the healthcare sector, serves on the boards of DexCom, Inc.
and LMS Medical Systems, Inc., and is Executive Chairman of Patton Medical
Devices, LC. Mr. Gregg also served on the Boards of Amylin Pharmaceuticals,
Inc. and Ocular Sciences, Inc., which was purchased by The Cooper Companies,
Inc. for US$1.2 billion last year.
    "Vasogen has an exciting future and I am pleased to assume the role of
President and CEO of a company with a solid scientific team and experienced
management who are committed to achieving success," stated Terrance Gregg. "As
a founder of Vasogen, David Elsley has provided visionary leadership since the
Company's inception and has positioned us well for the future. I look forward
to working with David as we transition from a development-stage company to a
successful commercial enterprise."
    "Terry Gregg's vision and his experience in transforming MiniMed from a
development-stage therapeutic device company to a global leader in diabetes
management systems will prove invaluable as we prepare for the
commercialization phase of Vasogen's Celacade technology," stated David
Elsley. "I am confident that the key findings from our ACCLAIM trial provide a
strong foundation to move to the next level of Vasogen's evolution and I look
forward to my continued involvement as an active member of the Board."
    The 2,408-patient phase III ACCLAIM trial of Vasogen's Celacade(TM)
technology (Celacade) in patients with chronic heart failure, completed in
2006, demonstrated strong results in two important pre-defined patient
subgroups. While the study did not meet its primary endpoint, Celacade was
shown to significantly reduce the risk of death or first cardiovascular
hospitalization by 39% in patients with NYHA Class II heart failure at
baseline (n=689, p=0.0003), and by 26% in patients with no prior history of
heart attack at baseline (n=919, p=0.02). The Company is currently pursuing
partnering discussions to support the initial commercialization of Celacade in
Europe on the basis of these results. The Company is also preparing to meet
with the FDA to review the ACCLAIM results for the purpose of determining the
next steps in the regulatory pathway for Celacade in the United States.

    About Vasogen:
    Vasogen is a biotechnology company engaged in the research and
development of therapies that target the damaging inflammation associated with
cardiovascular and neurodegenerative disorders. The Company's lead product,
the Celacade(TM) technology, is designed to trigger the immune response to
apoptosis - an important physiological process that regulates inflammation.
Celacade(TM) is in late-stage development for the treatment of chronic heart
failure. The Company is also developing VP025, an early-stage new drug
candidate for the treatment of certain neurodegenerative diseases.

    Certain statements contained in this press release or elsewhere in our
public documents constitute "forward-looking statements" within the meaning of
the United States Private Securities Litigation Reform Act of 1995 and/or
"forward-looking information" under the Securities Act (Ontario). These
statements may include, without limitation, summary statements relating to
results of the ACCLAIM trial in patients with chronic heart failure, plans to
advance the development of Celacade(TM), plans to fund our current activities,
statements concerning our partnering activities and health regulatory
submissions, strategy, future operations, future financial position, future
revenues, projected costs, prospects, plans and objectives of management. In
some cases, you can identify forward-looking statements by terminology such as
"may", "will", "should", "expects", "plans", "anticipates", "believes",
"estimated", "predicts", "potential", "continue", "intends", "could", or the
negative of such terms or other comparable terminology. We made a number of
assumptions in the preparation of these forward-looking statements, including
assumptions about the nature, size and accessibility of the market for
Celacade in the treatment of chronic heart failure, particularly in Europe,
the regulatory approval process leading to commercialization and the
availability of capital on acceptable terms to pursue the development of
Celacade, and the feasibility of additional trials. You should not place undue
reliance on our forward-looking statements which are subject to a multitude of
risks and uncertainties that could cause actual results, future circumstances
or events to differ materially from those projected in the forward-looking
statements. These risks include, but are not limited to, the outcome of
further analysis of the ACCLAIM trial results, the requirement or election to
conduct additional clinical trials, delays or setbacks in the regulatory
approval process, securing and maintaining corporate alliances, the need for
additional capital and the effect of capital market conditions and other
factors on capital availability, the potential dilutive effects of any
financing, risks associated with the outcome of our research and development
programs, the adequacy, timing and results of our clinical trials,
competition, market acceptance of our products, the availability of government
and insurance reimbursements for our products, the strength of intellectual
property, reliance on subcontractors and key personnel, losses due to
fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from
time to time in our public disclosure documents or other filings with the
Canadian and U.S. securities commissions or other securities regulatory
bodies. Additional risks and uncertainties relating to our Company and our
business can be found in the "Risk Factors" section of our Annual Information
Form and Form 20-F for the year ended November 30, 2006, as well as in our
later public filings. The forward-looking statements are made as of the date
hereof, and we disclaim any intention and have no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. Unless otherwise indicated, numerical values indicating
the statistical significance ("p-values") of results included in this document
are based on analyses that do not account for endpoint multiplicity.





For further information:

For further information: Glenn Neumann, Investor Relations, 2505
Meadowvale Blvd., Mississauga, ON, Canada, L5N 5S2, tel: (905) 817-2004, fax:
(905) 569-9231, www.vasogen.com, investor@vasogen.com

Organization Profile

VASOGEN INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890